In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate
- 268 Downloads
Although Chlamydia trachomatis resistance is not of great concern due to its excellent sensitivity to the currently recommended first-line antibiotics (azithromycin and doxycycline), clinical treatment failures have been reported and some of them were linked to laboratory proved resistance. The aim of this study was to determine in vitro susceptibility to azithromycin and doxycycline for 24 urogenital chlamydial strains isolated in Croatia—a country with the highest consumption of azithromycin in Europe and with very high antibiotic prescription rates. Fourteen isolates from cervical swabs, nine from male urethral swabs, and one isolate from expressed prostatic secretion were tested in McCoy cell culture system. All strains were susceptible to azithromycin and doxycycline with minimal inhibitory concentration for azithromycin and doxycycline ranging from 0.064 to 0.125 μg/mL and 0.016 to 0.064 μg/mL, and minimal chlamydicidal concentration ranging from 0.064 to 2.0 μg/mL and 0.032 to 1.0 μg/mL, respectively. Since we still lack information on whether C. trachomatis is evolving in vivo in response to antibiotic selection pressure, this kind of surveillance for resistance is essential in detecting shifts in antimicrobial susceptibilities.
KeywordsMinimal Inhibitory Concentration Doxycycline Azithromycin Prostatitis Chlamydia Trachomatis
This work is part of the project “Investigation of the etiology, epidemiology, diagnostics and treatment of patients with prostatitis syndrome” (P.I. Professor V. Skerk) funded by The Croatian National Foundation for Science, Higher Education and Technological Development (grant no. 04/30). Authors thank Vesna Seperic and Mirela Josipovic for the technical assistance.
- Centers for Disease Control and Prevention (2009) Sexually transmitted disease surveillance. Department of Health and Human Services, AtlantaGoogle Scholar
- Donati M, Di Francesco A, D’antuono A, Delucca F, Shurdhi A, Moroni A, Baldelli R, Cevenini R (2010) In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. Antimicrob Agents Chemother 54:5379–5380CrossRefPubMedGoogle Scholar
- Hiršl-Hećej V, Pustišek N, Sikanić-Dugić N, Domljan LM, Kani D (2006) Prevalence of chlamydial genital infection and associated risk factors in adolescent females at an urban reproductive health care center in Croatia. Collegium Anthropologicum 30:131–137Google Scholar
- Ljubin-Sternak S, Škerk V (2010) Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice. Med Glas Ljek Komore Zenicko-Doboj Kantona 7:26–31Google Scholar
- Škerk V, Krhen I, Lisić M, Begovac J, Roglić S, Škerk V, Sternak SL, Banaszak A, Strugar-Šuica J, Vuković J (2004) Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 24:188–191CrossRefPubMedGoogle Scholar